Estimation of population vaccination effectiveness from HIV vaccine trials

被引:0
|
作者
Haber, M [1 ]
机构
[1] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA
关键词
HIV/AIDS transmission; infectiousness; susceptibility; vaccine efficacy; vaccine trials; vaccination effectiveness;
D O I
10.1002/(SICI)1521-4036(199909)41:5<533::AID-BIMJ533>3.0.CO;2-B
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
LONGINI, DATTA, and HALLORAN (1996) proposed to design HIV vaccine trials in a way that will permit the simultaneous estimation of the vaccine effects on susceptibility to infection and on infectiousness of vaccine brak-throughs. The main feature of their design is the inclusion of steady partners of trial participants. They estimate four parameters from the vaccine trial: the probability that a susceptible person will become infected from his/her steady partner, the probability of becoming infected from outside the partnership, the vaccine efficacy for susceptibility and the vaccine efficacy for infectiousness. We show how the estimates of these parameters can be used to predict the attack rate in a given population during a specified period following mass-vaccination. This is an iterative method, as the attack rate depends on the HIV prevalence which, in turn, depends on the number of new cases during that period. The same method is also used to estimate the attack rate in that population during the same period in the absence of vaccination. The estimated attack rates allow us to estimate the population vaccination effectiveness, defined as the fraction HIV cases prevented by a vaccination program.
引用
收藏
页码:533 / 542
页数:10
相关论文
共 50 条
  • [1] Estimation of the population effectiveness of vaccination
    Haber, M
    [J]. STATISTICS IN MEDICINE, 1997, 16 (06) : 601 - 610
  • [2] Estimation of individual and population vaccination effectiveness from time-to-event data
    Haber, M
    Ndikuyeze, A
    [J]. STATISTICS IN MEDICINE, 1998, 17 (22) : 2617 - 2623
  • [3] NEW POPULATION, NEW HIV VACCINE IN CLINICAL-TRIALS
    MERZ, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (09): : 1290 - 1291
  • [4] HIV vaccine trials
    Des Jarlais, DC
    Vanichseni, S
    Marmor, M
    Kitayaporn, D
    [J]. SCIENCE, 1998, 279 (5356) : 1433 - 1434
  • [5] Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination
    Glass, Joshua J.
    Kent, Stephen J.
    De Rose, Robert
    [J]. EXPERT REVIEW OF VACCINES, 2016, 15 (06) : 719 - 729
  • [6] Vaccination against enteric pathogens: from science to vaccine trials
    Lindberg, AA
    [J]. CURRENT OPINION IN MICROBIOLOGY, 1998, 1 (01) : 116 - 124
  • [7] Lessons learned from human HIV vaccine trials
    Pollara, Justin
    Easterhoff, David
    Fouda, Genevieve G.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2017, 12 (03) : 216 - 221
  • [8] Measles, Mumps and Rubella Vaccination to Reduce the Risk of Measles During HIV Vaccine Trials
    Kelly, Hilary
    Tichacek, Amanda
    Kampamba, Sydney
    Parker, Rachel
    Sharkey, Tyronza
    Siyumbwa, Namukolo
    Mbewe, Maria
    Banda, Lucy
    Mwaanga, Annie
    Mulenga, Muyunda
    Mufonka, Mwamba
    Kolala, Sithokozile
    Mulenga, Muma
    Mumphansha, Chipo
    Michelo, Clive
    Kilembe, William
    Inambao, Mubiana
    Fast, Pat
    Priddy, Fran
    Allen, Susan
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 290 - 290
  • [9] HIV vaccine trials in India
    Seth Berkley
    [J]. Nature Biotechnology, 2008, 26 : 495 - 495
  • [10] HIV vaccine trials and tribulations
    不详
    [J]. LANCET INFECTIOUS DISEASES, 2009, 9 (11): : 651 - 651